Related references
Note: Only part of the references are listed.Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma
Leo Meriranta et al.
BLOOD (2022)
Cell-of-origin classification using the Hans and Lymph2Cx algorithms in primary cutaneous large B-cell lymphomas
Anne M. R. Schrader et al.
VIRCHOWS ARCHIV (2022)
Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL
Wyndham H. Wilson et al.
CANCER CELL (2021)
Histone H1 loss drives lymphoma by disrupting 3D chromatin architecture
Nevin Yusufova et al.
NATURE (2021)
Double expressor and double/triple hit status among primary cutaneous diffuse large B-cell lymphoma: a comparison between leg type and not otherwise specified subtypes
Marco Lucioni et al.
HUMAN PATHOLOGY (2021)
Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hit
Francesco Cucco et al.
LEUKEMIA (2020)
A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications
George W. Wright et al.
CANCER CELL (2020)
Influence of oncogenic mutations and tumor microenvironment alterations on extranodal invasion in diffuse large B-cell lymphoma
Rong Shen et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2020)
Mutations of the B-Cell Receptor Pathway Confer Chemoresistance in Primary Cutaneous Diffuse Large B-Cell Lymphoma Leg Type
Oceane Ducharme et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2019)
Addictive response of primary cutaneous diffuse large B cell lymphoma leg type to low-dose ibrutinib
Annie Pang et al.
ANNALS OF HEMATOLOGY (2019)
The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas
Rein Willemze et al.
BLOOD (2019)
High prevalence of MYD88 and CD79B mutations in intravascular large B-cell lymphoma
Anne M. R. Schrader et al.
BLOOD (2018)
Molecular Mechanisms of Disease Progression in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type during Ibrutinib Therapy
Lucy C. Fox et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell Lymphoma, Leg Type
Xiaolong Alan Zhou et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2018)
Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes
Bjoern Chapuy et al.
NATURE MEDICINE (2018)
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
R. Schmitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
High Incidence and Clinical Significance of MYC Rearrangements in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type
Anne M. R. Schrader et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2018)
Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma
David M. Kurtz et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Combination of ibrutinib and chemotherapy produced a durable remission in multiply relapsed diffuse large B-cell lymphoma leg type with mutant MYD88 and wildtype CD79
Andrew L. Deng et al.
HAEMATOLOGICA (2017)
Identification of Somatic Mutations in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type by Massive Parallel Sequencing
Sylvain Mareschal et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2017)
Non-invasive detection of somatic mutations using nextgeneration sequencing in primary central nervous system lymphoma
Maxime Fontanilles et al.
ONCOTARGET (2017)
Combination of ibrutinib and chemotherapy produced a durable remission in multiply relapsed diffuse large B-cell lymphoma leg type with mutant MYD88 and wildtype CD79
Andrew L. Deng et al.
HAEMATOLOGICA (2017)
Targetable genetic features of primary testicular and primary central nervous system lymphomas
Bjoern Chapuy et al.
BLOOD (2016)
Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA
Florian Scherer et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Recurrent targets of aberrant somatic hypermutation in lymphoma
Alireza Hadj Khodabakhshi et al.
Oncotarget (2015)
Excellent outcome of immunomodulation or Bruton's tyrosine kinase inhibition in highly refractory primary cutaneous diffuse large B-cell lymphoma, leg type
Eva Gupta et al.
RARE TUMORS (2015)
High Frequency and Clinical Prognostic Value of MYD88 L265P Mutation in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg-Type
Anne Pham-Ledard et al.
JAMA DERMATOLOGY (2014)
Fine-Mapping Chromosomal Loss at 9p21: Correlation with Prognosis in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type
Nancy J. Senff et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2009)
Reclassification of 300 primary cutaneous B-cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: Comparison with previous classifications and identification of prognostic markers
Nancy J. Senff et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Primary cutaneous follicle center lymphoma and primary cutaneous large B-cell lymphoma, leg type, are both targeted by aberrant somatic hypermutation but demonstrate differential expression of AID
Remco Dijkman et al.
BLOOD (2006)
Share Paper
